Streetbeat News

Regulatory

SXTP

60 Degrees Pharmaceuticals shares have risen following the announcement of IRB approval for a Phase IIA clinical study of tafenoquine for babesiosis.

Portfolio Pulse from Benzinga Newsdesk

December 26, 2023 | 1:39 pm

ZKIN

ZK International Group Co., Ltd. (NASDAQ:ZKIN) has resolved its Nasdaq bid price deficiency and is now in compliance with Nasdaq's minimum bid price requirement. The company's stock price remained above $1.00 for 10 consecutive business days, satisfying the Nasdaq Capital Market's Listing Rule 5550(a)(2). The Nasdaq Listing Qualifications Panel will continue listing ZKIN's securities, and the company has acknowledged the assistance of Donohoe Advisory Associates LLC in this matter.

Portfolio Pulse from Happy Mohamed

December 26, 2023 | 1:33 pm

TMUS

SoftBank Group Capital Ltd has filed an amended 13D with the SEC, reporting a 7.64% stake in T-Mobile US as of December 22, 2023.

Portfolio Pulse from Happy Mohamed

December 26, 2023 | 1:10 pm

CVRX

CVRx, Inc. (NASDAQ:CVRX) announced FDA approval for expanded labeling of Barostim based on long-term data from the BeAT-HF trial. The updated IFU reflects improved functional status and quality of life for heart failure patients. The U.S. market opportunity for Barostim is now estimated at $2.2 billion, a significant increase from previous estimates.

Portfolio Pulse from Happy Mohamed

December 26, 2023 | 1:06 pm

ADEX

Adit EdTech Acquisition Corp. (ADEX) has announced its plan to voluntarily de-list from the NYSE American. This decision follows the NYSE American's indication that it would not approve the listing of the post-closing company. ADEX has notified the NYSE American and plans to file a Form 25 with the SEC to proceed with the de-listing, expected to be effective around January 15, 2024. ADEX is seeking to list its common stock and warrants in the U.S. and Canada post its business combination with Griid Holdco LLC and will continue to file periodic reports with the SEC.

Portfolio Pulse from Happy Mohamed

December 26, 2023 | 1:05 pm

BCLI

BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI) has been granted patents in Europe, Australia, and Israel for its NurOwn and NurOwn-Exosomes technologies. These patents cover methods of qualifying cells for treating ALS and the use of specific exosomes derived from MSC-NTF cells for treating neurodegenerative diseases. The grants are expected to strengthen BrainStorm's intellectual property position in the field of neurodegenerative disease treatments.

Portfolio Pulse from Benzinga Newsdesk

December 26, 2023 | 12:31 pm

COP

ConocoPhillips (NYSE:COP) is proceeding with the Willow project in Alaska after receiving approval from the Department of the Interior and positive court rulings. The project, which faced opposition from environmentalists, is expected to generate significant revenue and create jobs, while reducing dependency on foreign energy. Despite the progress, COP shares dipped slightly in premarket trading.

Portfolio Pulse from Lekha Gupta

December 26, 2023 | 12:08 pm

ASML

INTC

Intel Corporation (NASDAQ:INTC) is set to receive a $3.2 billion grant from the Israeli government for a new $25 billion chip plant in Israel, with operations starting in 2027. Intel has committed to purchasing $16.6 billion in goods and services from Israeli suppliers over the next decade. The company is actively progressing with the construction of the site, which is part of its global supply chain resilience efforts. ASML Holding NV (NASDAQ:ASML) has started shipping components for a new chipmaking machine to Intel's Oregon factory.

Portfolio Pulse from Nabaparna Bhattacharya

December 26, 2023 | 12:02 pm

MIST

Milestone Pharmaceuticals has received a Refusal to File letter from the FDA regarding their New Drug Application for etripamil nasal spray, intended for the treatment of paroxysmal supraventricular tachycardia.

Portfolio Pulse from Benzinga Newsdesk

December 26, 2023 | 12:02 pm

TM

Daihatsu, a subsidiary of Toyota Motor Corp (NYSE:TM), is compensating its 423 domestic suppliers in Japan due to a production halt following a safety test scandal. The compensation is based on past business volumes. The production stoppage is a result of safety test manipulations found in 64 models, some under the Toyota brand. Daihatsu is also considering support for smaller subcontractors. Production of Perodua brand cars in Malaysia and shipments from PT Astra Daihatsu Motor in Indonesia have resumed.

Portfolio Pulse from Anan Ashraf

December 26, 2023 | 11:50 am